NimbleGen gives Roche entry into microarrays
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is poised to enter the microarray systems market after signing a definitive agreement to purchase high-density DNA microarray developer NimbleGen Systems in a $272.5m deal. The merger will see NimbleGen (Madison, Wisconsin) develop and market array systems through Roche's diagnostics arm Roche Applied Science (RAS), whilst also expanding its portfolio to include higher density arrays, integrated instrument systems and related reagents for advanced genome analysis.